ICON plc

  • Market Cap: Small Cap
  • Industry: Miscellaneous
  • ISIN: IE0005711209
USD
185.77
2.63 (1.44%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

1.65 M

Shareholding (Mar 2025)

FII

29.33%

Held by 272 FIIs

DII

29.33%

Held by 52 DIIs

Promoter

0.19%

How big is ICON plc?

22-Jun-2025

As of Jun 18, ICON plc has a market capitalization of 11,456.17 million, with net sales of 8,192.62 million and a net profit of 758.19 million over the latest four quarters.

Market Cap: As of Jun 18, ICON plc has a market capitalization of 11,456.17 million, categorizing it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, ICON plc reported net sales of 8,192.62 million and a net profit of 758.19 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 9,523.00 million, while total assets were reported at 16,877.68 million.

Read More

What does ICON plc do?

22-Jun-2025

ICON plc is a contract research organization (CRO) that offers outsourced development services to the pharmaceutical, biotechnology, and medical device industries. As of March 2025, it reported net sales of $2,001 million and a market cap of $11.46 billion.

Overview:<BR>ICON plc is a contract research organization (CRO) that provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries, operating within the Miscellaneous industry and classified as a Large Cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 2,001 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 154 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 11,456.17 Million (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 12.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.30 <BR>Return on Equity: 9.52% <BR>Price to Book: 1.21 <BR><BR>Contact Details:<BR>Address: South County Business Park, Dublin 18, DUBLIN None: 00000 <BR>Tel: ['353 1 2912000', '1 888 3817923'] <BR>Fax: 353 1 2912700 <BR>Website: http://www.iconplc.com/

Read More

Who are in the management team of ICON plc?

22-Jun-2025

As of March 2022, the management team of ICON plc includes Non-Executive Chairman Mr. Ciaran Murray, CEO Dr. Stephen Cutler, Lead Independent Director Mr. Ronan Murphy, and Independent Directors Prof. Hugh Brady, Dr. John Climax, and Ms. Joan Garahy. They are responsible for the company's strategic direction and governance.

As of March 2022, the management team of ICON plc includes the following members:<BR><BR>- Mr. Ciaran Murray, who serves as the Non-Executive Chairman of the Board.<BR>- Dr. Stephen Cutler, who is the Chief Executive Officer and a Director.<BR>- Mr. Ronan Murphy, who holds the position of Lead Independent Director.<BR>- Prof. Hugh Brady, who is an Independent Director.<BR>- Dr. John Climax, who is also an Independent Director.<BR>- Ms. Joan Garahy, who serves as an Independent Director.<BR><BR>This team plays a crucial role in guiding the strategic direction and governance of the company.

Read More

Should I buy, sell or hold ICON plc?

22-Jun-2025

Is ICON plc overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, ICON plc's valuation has shifted from very attractive to attractive, indicating it may be overvalued with a P/E ratio of 12 compared to peers, and despite a favorable EV to EBITDA ratio, its poor performance relative to the S&P 500 suggests limited growth prospects.

As of 17 October 2025, the valuation grade for ICON plc has moved from very attractive to attractive, indicating a shift in perception. The company appears to be overvalued based on its current metrics, with a P/E ratio of 12, which is lower than the peer average of approximately 15.81 for Booz Allen Hamilton Holding Corp. and 27.84 for Charles River Laboratories International, suggesting that ICON plc is trading at a discount compared to some of its peers. Additionally, the EV to EBITDA ratio stands at 8.19, which is more favorable than the industry average, but the PEG ratio of 0.55 indicates potential growth at a reasonable price.<BR><BR>In terms of performance, ICON plc has underperformed compared to the S&P 500, with a year-to-date return of -11.75% versus the index's 13.30%. Over one year, the stock has declined by 37.32%, while the S&P 500 has gained 14.08%. This stark contrast in returns reinforces the notion that ICON plc may be overvalued relative to its growth prospects and market performance.

Read More

Is ICON plc technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, ICON plc shows a mildly bullish trend in daily moving averages, but significant underperformance against the S&P 500 and bearish signals in other indicators suggest caution.

As of 31 October 2025, the technical trend for ICON plc has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly MACD is bullish, although the monthly MACD is bearish. Other indicators such as the Bollinger Bands and KST are bearish on both weekly and monthly time frames. The Dow Theory shows no trend in both weekly and monthly assessments. <BR><BR>Despite the mildly bullish trend, the company has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -22.29% versus the S&P 500's 16.30%, and a one-year return of -26.06% compared to the S&P 500's 19.89%. Overall, the current technical stance is mildly bullish, but the strength is tempered by bearish signals in other indicators and significant underperformance against the benchmark.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

The company has declared negative results in Mar'2025 after 5 consecutive positive quarters

  • DEBTORS TURNOVER RATIO(HY) Lowest at 2.82 times
  • OPERATING PROFIT(Q) Lowest at USD 366.19 MM
  • OPERATING PROFIT MARGIN(Q) Lowest at 18.15 %
2

With ROCE of 9.61%, it has a fair valuation with a 1.14 Enterprise value to Capital Employed

3

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Miscellaneous

stock-summary
Market cap

USD 13,829 Million (Small Cap)

stock-summary
P/E

12.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.32

stock-summary
Return on Equity

9.88%

stock-summary
Price to Book

1.45

Revenue and Profits:
Net Sales:
2,017 Million
(Quarterly Results - Jun 2025)
Net Profit:
183 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3.2%
0%
3.2%
6 Months
38.88%
0%
38.88%
1 Year
-12.78%
0%
-12.78%
2 Years
-31.03%
0%
-31.03%
3 Years
-12.81%
0%
-12.81%
4 Years
-31.9%
0%
-31.9%
5 Years
-6.8%
0%
-6.8%

ICON plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
23.90%
EBIT Growth (5y)
23.49%
EBIT to Interest (avg)
9.73
Debt to EBITDA (avg)
2.07
Net Debt to Equity (avg)
0.30
Sales to Capital Employed (avg)
0.62
Tax Ratio
8.34%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
12.28%
ROE (avg)
9.42%
Valuation key factors
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
1.18
EV to EBIT
11.86
EV to EBITDA
8.19
EV to Capital Employed
1.14
EV to Sales
1.72
PEG Ratio
0.55
Dividend Yield
NA
ROCE (Latest)
9.61%
ROE (Latest)
9.52%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 144 Schemes (41.11%)

Foreign Institutions

Held by 272 Foreign Institutions (29.33%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -4.85% vs 4.94% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 24.57% vs 27.08% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,017.40",
          "val2": "2,120.20",
          "chgp": "-4.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "366.20",
          "val2": "440.00",
          "chgp": "-16.77%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "50.20",
          "val2": "60.80",
          "chgp": "-17.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-49.70",
          "val2": "-52.60",
          "chgp": "5.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "183.00",
          "val2": "146.90",
          "chgp": "24.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "128.30%",
          "val2": "133.20%",
          "chgp": "-0.49%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 1.99% vs 4.89% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 29.27% vs 21.18% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "8,281.70",
          "val2": "8,120.20",
          "chgp": "1.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,729.70",
          "val2": "1,686.10",
          "chgp": "2.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "237.20",
          "val2": "336.70",
          "chgp": "-29.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-121.70",
          "val2": "-89.60",
          "chgp": "-35.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "791.50",
          "val2": "612.30",
          "chgp": "29.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "145.10%",
          "val2": "130.40%",
          "chgp": "1.47%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
2,017.40
2,120.20
-4.85%
Operating Profit (PBDIT) excl Other Income
366.20
440.00
-16.77%
Interest
50.20
60.80
-17.43%
Exceptional Items
-49.70
-52.60
5.51%
Consolidate Net Profit
183.00
146.90
24.57%
Operating Profit Margin (Excl OI)
128.30%
133.20%
-0.49%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is -4.85% vs 4.94% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 24.57% vs 27.08% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
8,281.70
8,120.20
1.99%
Operating Profit (PBDIT) excl Other Income
1,729.70
1,686.10
2.59%
Interest
237.20
336.70
-29.55%
Exceptional Items
-121.70
-89.60
-35.83%
Consolidate Net Profit
791.50
612.30
29.27%
Operating Profit Margin (Excl OI)
145.10%
130.40%
1.47%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 1.99% vs 4.89% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 29.27% vs 21.18% in Dec 2023

stock-summaryCompany CV
About ICON plc stock-summary
stock-summary
ICON plc
Miscellaneous
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies. Its services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. The Company's information systems offerings include ICONIK, Firecrest, ADDPLAN, AptivAdvantage and Aptiv Insite. It conducts various laboratory tests on the patient's blood, urine and other bodily fluids at appropriate intervals during the trial. The Company offers clinical development services, including investigator recruitment, patient registries, outcomes research, clinical data management, immunoassay development and others.
Company Coordinates stock-summary
Company Details
South County Business Park, Dublin 18 , DUBLIN None : 00000
stock-summary
Tel: 353 1 29120001 888 3817923
stock-summary
Registrar Details